Skip to main content

Dr Mymoona Alzouebi

Consultant Clinical Oncologist

MBChB, MRCP, DTMH, MSc Oncology, FRCR

Practises at: Thornbury Hospital

Dr-Mymoona-Alzouebi-Oncology

Personal profile

Dr Alzouebi is Consultant Clinical Oncologist specialising in the treatment of cancers of the urinary tract. Her areas of interest are in the treatment of prostate, kidney and bladder cancer with systemic anti-cancer chemotherapy, immunotherapy and radiotherapy.

She is an expert in cancer care, using the most advanced and up to date treatment modalities. She is actively involved in clinical trials and research and is the local Principal Investigator on several national clinical trials.

Dr Alzouebi holds a substantive NHS post as a Consultant Clinical Oncologist at Weston Park Hospital; Sheffield Teaching Hospital NHS Foundation Trust.

She qualified from the University of Sheffield in 2004, and undertook general medical training in the Yorkshire Deanery, achieving MRCP and DTMH qualifications.

She completed the Clinical Oncology Training Programme at Weston Park Hospital in Sheffield and obtained a Distinction in a Master’s Degree in Oncology from the University of Nottingham. Her dissertation research was published in a peer-reviewed journal.

Dr Alzouebi successfully obtained her Fellow of Royal College of Radiologist (Clinical Oncology) qualification in 2012.

Current NHS and /or University Posts

  • Consultant in Clinical Oncology in Urological Malignancies at Weston Park Cancer Centre, Sheffield

Research Interests

  • M Alzouebi, R Jones. Outcomes of 10 years prescribing practice for first line metastatic kidney cancer. NCRI 2018.
  • M Alzouebi, JR Goepel, JM Horsman and BW Hancock. Primary
Research Publications
  • M Alzouebi, R Jones. Outcomes of 10 years prescribing practice for first line metastatic kidney cancer. NCRI 2018
  • M Alzouebi, JR Goepel, JM Horsman and BW Hancock. Primary thyroid lymphoma: The 40-year experience of a UK lymphoma treatment centre. Int J Oncol 40: 2075-2080, 2012
  • M Alzouebi, S Pledge and J Martin. Are outcomes of adjuvant vaginal vault brachytherapy in endometrial cancer related to the way it is delivered? Journal of Radiotherapy in Practice. FirstView Article : pp 1-14 Published online: 12 December 2011
  • M Alzouebi, P Fisher, PJ Woll, MQ Hatton, BH Foran. Audit of adjuvant vinorelbine and cisplatin for patients with resected NSCLC. Lung Cancer 2010;67:S1
  • M Alzouebi, P Sarrigiannis, M Hadjivassiolou. Acute Polyradiculopathy with renal failure; mind the anion gap – Journal of Neurology, Neurophysiology and Psychiatry Psychiatry 2008;79:842-844
  • M Alzouebi. Paediatric Chest Radiographs. StudentBMJ 2005; 13:309-352
  • M Alzouebi, M McAlindon, DS Sanders. Patients starving before percutaneous endoscopic gastrostomy (PEG) placement may be at risk of refeeding syndrome. BAPEN 2004; 63 (1)

Clinical interests

  • Radiotherapy
  • Chemotherapy
  • Biological treatment
  • Novel targeted anticancer drug treatment
  • Intensity Modulated Radiotherapy (IMRT)
  • Prostate cancer
  • Bladder cancer
  • Kidney cancer
  • IMRT
  • IGRT
  • Adaptive radiotherapy
  • Systemic chemotherapy
  • Immunotherapy
  • Monoclonal antibodies
  • Biological therapy
  • Endocrine oncology
  • Urological cancers
  • Stereotactic ablative radiotherapy
  • SABR
  • Radium-223

Professional memberships

  • General Medical Council
  • Royal College of Radiologists
  • British Uro-Oncology Group
i